今日晚间，合富中国发布公告称，自2025年10月28日至2025年11月14日期间，公司股票连续十四个交易日中有十二个交易日以涨停价收盘，并5次触及股价 异常波动、3次触及严重异常波动情形，期间累计涨幅高达256.29%，已明显高于同期行业及上证指数涨幅。 公告提示，股价短期内连续上涨，存在市场情绪过热、非理性炒作风险，随时存在快速下跌风险可能。公司股票流通换手率亦出现较大波动情形，击鼓传花 效应明显，投资者参与交易可能面临较大风险。 半个月股价涨超2.5倍的大牛股合富中国宣布停牌核查。 公告称，公司已于2025年11月13日进一步提示，股价涨幅已严重显著偏离公司基本面，投资者参与交易可能面临较大风险；如公司股价继续异常上涨，可能 申请停牌核查。11月14日，公司股价继续大幅上涨，盘中一度触及涨停，换手率高达28.48%。公司股票将于2025年11月17日（星期一）开市起停牌，预计停 牌时间不超过3个交易日，公司股票将自披露核查公告后复牌。公司提醒广大投资者注意二级市场交易风险。 公开资料显示，合富中国主营业务是以体外诊断相关的医疗设备及其耗材为主的国际贸易、售后服务，贸易代理，医院信息管理系统的咨询服务以及 ...

官网资料介绍，合富集团是目前唯一一家两岸双上市的医疗企业，旗下合富医疗控股股份有限公司于台 湾证券柜台买卖中心上柜，合富（中国）医疗科技股份有限公司于上海证券交易所主板上市。 合富于2000年在上海成立运营总部。公司称，其创立是为了提升大中华医疗水平，期盼让所有的医院能 够拥有世界一流的医疗设备，使绝大部分人群可以享受到世界先进的医疗技术。一直以来，合富始终以 建构优质的医疗服务体系和促进大健康产业发展为使命，通过科技及服务模式的双创新，为医院提升竞 争力。 合富中国11月14日公告，自2025年10月28日至2025年11月14日期间，公司股票连续十四个交易日中有十 二个交易日以涨停价收盘，并5次触及股价异常波动、3次触及严重异常波动情形，期间累计涨幅高达 256.29%，已明显高于同期行业及上证指数涨幅。股价短期内连续上涨，存在市场情绪过热、非理性炒 作风险，随时存在快速下跌可能。为维护广大投资者利益，公司将就上述股票交易波动情况进行核查。 经向上海证券交易所申请，公司股票将于2025年11月17日（星期一）开市起停牌，自披露核查公告后复 牌。 本文系观察者网独家稿件，未经授权，不得转载。 ...

合富中国（603122）(603122.SH)发布公告，自2025年10月28日至2025年11月14日期间，公司股票连续 十四个交易日中有十二个交易日以涨停价收盘，并5次触及股价异常波动、3次触及严重异常波动情形， 期间累计涨幅高达256.29%，已明显高于同期行业及上证指数涨幅。股价短期内连续上涨，存在市场情 绪过热、非理性炒作风险，随时存在快速下跌可能。公司股票将于2025年11月17日(星期一)开市起停 牌，预计停牌时间不超过3个交易日，公司股票将自披露核查公告后复牌。 ...

Core Viewpoint - The stock of HeFu China (603122.SH) has experienced a significant increase, with a total rise of 256.29% over a period where it closed at the limit-up price for 12 out of 14 trading days, indicating potential market overheating and irrational speculation [1] Summary by Relevant Sections - **Stock Performance** - The stock price increased by 256.29% during the period from October 28, 2025, to November 14, 2025, with 12 out of 14 trading days closing at the limit-up price [1] - The stock has encountered 5 instances of abnormal price fluctuations and 3 instances of severe abnormal fluctuations during this period [1] - **Market Context** - The stock's performance has significantly outpaced the industry and the Shanghai Composite Index during the same timeframe [1] - **Trading Suspension** - The stock will be suspended from trading starting November 17, 2025, for a period not exceeding 3 trading days, pending the disclosure of a verification announcement [1]

公司已于2025年11月13日进一步提示，股价涨幅已严重显著偏离公司基本面，投资者参与交易可能面临 较大风险；如公司股价继续异常上涨，可能申请停牌核查。11月14日，公司股价继续大幅上涨，盘中一 度触及涨停，换手率高达28.48%。为维护广大投资者利益，根据《上海证券交易所上市公司自律监管 指引第4号——停复牌》《上海证券交易所股票上市规则》等相关规定，经向上海证券交易所申请，本 公司股票将于2025年11月17日（星期一）开市起停牌，预计停牌时间不超过3个交易日，公司股票将自 披露核查公告后复牌。公司提醒广大投资者注意二级市场交易风险。 格隆汇11月14日丨合富中国(603122.SH)公布，自2025年10月28日至2025年11月14日期间，公司股票连 续十四个交易日中有十二个交易日以涨停价收盘，并5次触及股价异常波动、3次触及严重异常波动情 形，期间累计涨幅高达256.29%，已明显高于同期行业及上证指数涨幅。股价短期内连续上涨，存在市 场情绪过热、非理性炒作风险，随时存在快速下跌可能。 ...

每经AI快讯，合富中国（SH 603122，收盘价：23.8元）11月14日晚间发布公告称，自2025年10月28日 至2025年11月14日期间，公司股票连续十四个交易日中有十二个交易日以涨停价收盘，并5次触及股价 异常波动、3次触及严重异常波动情形，期间累计涨幅高达256.29%，已明显高于同期行业及上证指数 涨幅。股价短期内连续上涨，存在市场情绪过热、非理性炒作风险，随时存在快速下跌可能。 公司已于2025年11月13日进一步提示，股价涨幅已严重显著偏离公司基本面，投资者参与交易可能面临 较大风险；如公司股价继续异常上涨，可能申请停牌核查。11月14日，公司股价继续大幅上涨，盘中一 度触及涨停，换手率高达28.48%。为维护广大投资者利益，根据《上海证券交易所上市公司自律监管 指引第4号——停复牌》《上海证券交易所股票上市规则》等相关规定，经向上海证券交易所申请，本 公司股票将于2025年11月17日（星期一）开市起停牌，预计停牌时间不超过3个交易日，公司股票将自 披露核查公告后复牌。公司提醒广大投资者注意二级市场交易风险。 2024年1至12月份，合富中国的营业收入构成为：商业占比99.96%，其他业 ...

*ST正平公告称，公司股票11月12 - 14日收盘价格涨幅偏离值累计超12%，属异常波动。2025年三季度 累计营收6.52亿元，同比降20.92%；归母净利润 - 0.99亿元，同比降16%；扣非后归母净利润 - 1.90亿 元，同比降128.37%。公司提示多项风险，包括股价短期涨幅脱离基本面、存在终止上市风险、可能有 其他资金占用、矿产开采能力不足及业绩持续亏损等。 ...

Core Viewpoint - The stock price of ST Zhengping has experienced an extraordinary surge, significantly diverging from the company's fundamental performance, raising regulatory concerns about market speculation and irrational trading behavior [1][4][6]. Group 1: Stock Price Surge - ST Zhengping's stock has seen an astonishing increase of over 170% since early September [3]. - The stock's short-term gains have deviated sharply from the Shanghai Composite Index and the construction industry index, indicating a disconnect from the company's fundamentals [4]. - Despite multiple risk warning announcements and two trading suspensions for verification, market speculation remains high, with the stock hitting consecutive daily price limits upon resumption [2][5][6]. Group 2: Underlying Risks - The company faces significant fundamental risks, including the threat of delisting due to an audit report that could not express an opinion for the 2024 annual report, leading to a delisting risk warning [7]. - The 2024 internal control audit report received a negative opinion, raising uncertainties about the company's ability to continue operations, alongside issues of illegal guarantees [7][8]. - The company has reported substantial losses for both 2024 and the first three quarters of 2025 [9]. Group 3: Legal and Financial Challenges - ST Zhengping is currently embroiled in numerous lawsuits and arbitration cases, with substantial amounts at stake, further complicating its financial situation [10]. - The company has resolved previous non-operational fund occupation issues, but uncertainties remain regarding undisclosed non-operational fund occupations [11]. - The company's wholly-owned subsidiary faces challenges in mineral resource extraction due to insufficient funds, personnel, and equipment, leading to significant uncertainty about future development and revenue generation [11]. Group 4: New Business Ventures - The company is actively exploring new growth areas, including renewable energy construction and intelligent computing services, and has established partnerships with various local governments and enterprises [12][13]. - However, the effectiveness of these new ventures in reversing the company's current predicament remains to be seen, and the company continues to caution investors about the risks associated with the recent stock price surge [14].

Core Viewpoint - The stock price of HeFu China has significantly deviated from its fundamentals, leading to a warning about potential risks for investors, especially after a substantial increase in stock price over the past month [1][5]. Group 1: Stock Performance - HeFu China's stock price has seen a cumulative increase of 244.24% since October, with a market capitalization reaching 8.8 billion [1][3]. - From October 28 to November 13, the stock price rose by 230.84%, with 12 out of 13 trading days closing at the daily limit [3]. Group 2: Financial Performance - For the first three quarters, HeFu China reported a revenue of 549 million, a year-on-year decline of 22.80%, and a net loss attributable to shareholders of 12.39 million, a decrease of 146.65% [6]. - In the third quarter alone, the net loss was 5.05 million, representing a decline of 225.26% compared to the same period last year [6]. Group 3: Business Operations - The company attributes the decline in revenue and profit to reduced procurement prices and a decrease in order volumes, despite implementing cost control measures [7]. - HeFu China maintains that its production and operational activities are normal, with no significant changes in the internal and external business environment [7].

Core Viewpoint - The stock price of HeFu China (603122.SH) has significantly deviated from its fundamentals, leading to potential risks for investors, with a cumulative increase of 230.84% over a period of thirteen trading days, raising concerns about market overheating and irrational speculation [1][5]. Group 1: Stock Performance - As of November 13, the stock price of HeFu China closed at 22.10 CNY per share, reaching a historical high, with a market capitalization of 8.797 billion CNY [3][4]. - The stock has experienced twelve out of thirteen consecutive trading days closing at the limit-up price, indicating extreme volatility [1]. Group 2: Financial Performance - HeFu China's Q3 report shows a revenue of 549 million CNY for the first three quarters, a year-on-year decline of 22.80%, and a net loss of 12.3862 million CNY, a decrease of 146.65% compared to the previous year [5]. - The company has faced a continuous decline in performance since its peak in 2022, with revenues dropping from 1.28 billion CNY in 2022 to 939 million CNY in 2024, and net profits shrinking from 82.7197 million CNY to 27.5663 million CNY [5]. - The decline in performance is attributed to policy adjustments in the medical industry, leading to reduced procurement prices and order volumes from hospital clients, which has not been fully offset by cost control measures [5].